CPS1 Antibody

What is CPS1 and why is it significant in biomedical research?

CPS1 is a multidomain mitochondrial enzyme that functions as the rate-limiting first step of the urea cycle. Its biological significance extends across multiple research areas:

• Primary Function: Produces carbamoyl phosphate from ammonia and bicarbonate to initiate nitrogen disposal

• Metabolic Pathways: Critical for arginine biosynthesis and pyrimidine metabolism

• Disease Relevance: Implicated in liver diseases (hepatitis C, hepatic fibrosis), congenital CPS1 deficiency, and multiple cancer types

• Cancer Biology: Maintains pyrimidine/purine balance in cancer cells, particularly in KRAS-mutant cancers with LKB1 loss

• Cardiovascular Research: The T1405N variant (found in 30% of the population) has been associated with cardiovascular conditions

The broad implications of CPS1 across multiple pathological conditions make CPS1 antibodies essential tools for investigating these disease mechanisms and potential therapeutic strategies.

What types of CPS1 antibodies are available and how should they be selected for specific applications?

When selecting a CPS1 antibody, researchers must consider several technical parameters to match their experimental requirements:

Methodological considerations for antibody selection:

• Application-specific criteria: For Western blotting, standard dilution is typically 1:1000 . For immunohistochemistry, consider antibodies validated with appropriate fixation methods .

• Epitope recognition: Some antibodies target N-terminal regions (e.g., RM395) , while others target C-terminal epitopes , which may affect detection of truncated variants.

• Cross-reactivity: Verify species cross-reactivity experimentally even when predicted from sequence homology .

• Validation methods: Review the validation data provided (Western blots, IHC images) to ensure the antibody performs as expected in your specific application .

How can researchers troubleshoot issues with CPS1 antibody specificity and sensitivity?

Researchers often encounter technical challenges when working with CPS1 antibodies. Addressing these methodologically requires:

Specificity validation approaches:

• Positive controls: Use liver tissue/cells as positive controls since CPS1 is predominantly expressed in hepatocytes .

• Negative controls: Use tissues known to lack CPS1 expression or CPS1-knockdown samples.

• Expected molecular weight: Confirm detection at the expected 165 kDa band (primary CPS1 form), though some sources mention a 116 kDa variant .

• Multiple antibody approach: Use antibodies recognizing different epitopes to confirm findings and rule out non-specific binding.

Sensitivity optimization strategies:

• Sample preparation: For mitochondrial proteins like CPS1, ensure complete cell lysis and mitochondrial membrane disruption using appropriate buffers.

• Signal enhancement: Consider using amplification systems (HRP-polymer, tyramide) for IHC applications with low abundance targets.

• Buffer optimization: When immunoprecipitating CPS1, use phosphate-buffered saline with stabilizers (0.09% sodium azide, 1% BSA, 50% glycerol) .

• Subcellular localization: For accurate ICC/IF results, ensure proper permeabilization to access the mitochondrial matrix where CPS1 resides .

What experimental considerations are important when studying CPS1 in cancer research?

CPS1 has emerged as a significant player in cancer biology, with altered expression profiles across multiple tumor types. For cancer researchers:

Methodological recommendations:

• Expression profiling: Use CPS1 antibodies to assess differential expression between tumor and adjacent normal tissues. CPS1 is upregulated in liver, colorectal, stomach, cervical, and pancreatic cancers .

• Metabolic function assessment: Combine CPS1 protein expression data with metabolic assays to correlate CPS1 levels with pyrimidine synthesis rates in cancer cells .

• Regulatory mechanisms: Investigate p53-mediated repression of CPS1, as research shows tumor suppressor p53 represses urea cycle enzymes including CPS1 .

• Epigenetic regulation: Assess whether hypermethylation affects CPS1 expression, as studies suggest this mechanism contributes to hepatocellular carcinoma progression .

Recent research insights:

• Silencing CPS1 reduces the pyrimidine to purine ratio and stalls DNA synthesis, leading to DNA damage and cancer cell death .

• Small molecule CPS1 inhibitors (H3B-120 and H3B-616) that block ATP hydrolysis show promise as targeted anti-cancer compounds .

• The CPS1-derived long non-coding RNA CPS1-IT1 has anti-tumor properties, with higher expression correlating with better prognosis in multiple cancer types .

How can CPS1 antibodies be utilized to study urea cycle disorders and CPS1 deficiency?

CPS1 deficiency represents one of the most severe urea cycle disorders, with high mortality rates without treatment. Researchers studying these conditions should:

Recommended methodological approaches:

• Protein expression analysis: Use quantitative Western blotting with CPS1 antibodies to assess protein levels in patient samples compared to controls.

• Localization studies: Employ immunohistochemistry or immunofluorescence to determine if CPS1 is properly localized to mitochondria in patient samples.

• Functional correlation: Combine antibody-based protein detection with enzymatic activity assays to relate CPS1 protein levels to functional status.

• Therapeutic monitoring: Use CPS1 antibodies to track protein expression in experimental treatments, including liver transplantation and emerging gene therapies.

Clinical research context:

• Neonatal CPS1 deficiency has mortality rates up to 50% despite treatment, while late-onset forms have >90% survival .

• Long-term neurological deficits occur in most neonatal cases and a smaller proportion of late-onset cases .

• Current management focuses on dietary protein restriction and nitrogen scavenging compounds, highlighting the need for improved therapeutic options .

What role do post-translational modifications play in CPS1 regulation and how can antibodies help study these mechanisms?

CPS1 activity is heavily regulated by post-translational modifications that affect its enzymatic function. Investigating these regulatory mechanisms requires:

Advanced experimental strategies:

• Modification-specific detection: When available, use antibodies that specifically recognize modified forms of CPS1 (acetylated, succinylated, glutarylated).

• Co-immunoprecipitation: Use CPS1 antibodies to pull down protein complexes and probe for regulatory proteins such as Sirt5, which deacetylates and deglutarylates CPS1 .

• Temporal analysis: Track changes in CPS1 modification status under different physiological conditions (fasting, high protein intake) or in response to hormonal signals (glucagon).

• Inhibitor studies: Assess how inhibitors of regulatory enzymes (e.g., Sirt5 inhibitors) affect CPS1 modification status and enzymatic activity.

Regulatory insights:

• Sirt5 removes inhibitory protein modifications from critical cysteines in ATP binding sites of CPS1 .

• Glucagon increases intramitochondrial N-acetylglutamate (NAG) concentration, an essential allosteric activator of CPS1 .

• miR-19b negatively regulates Sirt5 during low protein intake, ultimately reducing CPS1 activity .

• AMPK inhibits Sirt5, potentially as a response to urea cycle flow and AMP generation .

How can researchers integrate CPS1 antibody-based techniques with other molecular approaches for comprehensive pathway analysis?

To fully understand CPS1's role in metabolic networks, researchers should combine antibody-based detection with complementary approaches:

Integrated methodological strategies:

• Multi-omics correlation: Relate protein expression (via antibody detection) with transcriptomic data (RNA-seq) and metabolomic profiles (mass spectrometry).

• Enzyme cascade analysis: Study the entire urea cycle by combining antibodies against multiple enzymes (CPS1, OTC, ASS1, ASL, ARG1).

• CRISPR-engineered models: Create cell lines with CPS1 mutations or tagged variants for functional studies, using antibodies to validate these models.

• Metabolic flux analysis: Combine antibody-based protein quantification with isotope tracing to relate CPS1 levels to metabolic pathway activity.

Application-specific recommendations:

• For studying genetic variants like T1405N (found in 30% of the population), combine genotyping with antibody-based protein analysis to assess functional impacts .

• In developmental studies, consider age-dependent expression differences, as newborns have lower CPS1 expression than adults .

• For tissue-specific studies, account for the predominant expression in liver and intestinal epithelial cells when interpreting antibody staining patterns .

What considerations are important when using CPS1 antibodies for immunohistochemistry in clinical and research settings?

Immunohistochemical detection of CPS1 requires specific technical considerations:

Optimization strategies:

• Fixation methods: Paraformaldehyde fixation is recommended for CPS1 detection in cells and tissues .

• Antigen retrieval: Due to its mitochondrial localization, heat-induced epitope retrieval may be necessary to expose CPS1 epitopes.

• Permeabilization: Complete permeabilization (e.g., with Triton X-100) is essential to access mitochondrial proteins like CPS1 .

• Signal detection: For mitochondrial staining patterns, confocal microscopy may provide better resolution of subcellular localization.

Interpretative guidelines:

• Normal liver shows strong granular cytoplasmic staining reflecting mitochondrial localization.

• CPS1 antibodies like Hep Par-1 have been used as diagnostic markers in liver biopsies .

• In cancer tissues, staining intensity may correlate with disease progression and prognosis.

• Co-staining with mitochondrial markers can confirm proper subcellular localization.

How can genetic variants of CPS1 impact antibody selection and experimental design?

Genetic variations in CPS1 can affect both protein function and antibody recognition:

Methodological implications:

• Variant-specific detection: For common variants like T1405N (affecting 30% of the population), antibody epitope selection may impact detection efficacy .

• Polymorphism considerations: When studying diverse populations, consider how genetic variations might affect antibody binding and experiment interpretation.

• Mutation analysis: For CPS1 deficiency studies, select antibodies that can detect truncated or misfolded proteins resulting from pathogenic mutations.

• Epitope mapping: When inconsistent results occur across samples, determine if genetic variations within the antibody's epitope region might be responsible.

Research applications:

• The T1405N variant has been associated with protection against neonatal hypertension and may represent an important marker for personalized medicine .

• This variant correlates with hyperammonemia in epilepsy patients receiving valproic acid, demonstrating how environmental stressors may interact with genetic variants .

• For CPS1 variants with altered subcellular localization, combining antibody detection with fractionation techniques can provide valuable insights.

What emerging areas of CPS1 research can benefit from advanced antibody-based techniques?

Several cutting-edge research directions can leverage CPS1 antibodies:

Therapeutic development approaches:

• Small molecule screening: Use antibody-based assays to evaluate how potential CPS1 inhibitors (like H3B-120 and H3B-616) affect protein expression and localization .

• Gene therapy assessment: Monitor CPS1 expression in experimental gene therapy models for CPS1 deficiency using quantitative antibody-based techniques.

• N-carglumic acid mechanism: Investigate how this NAG analog, which increased CPS1 activity yet inhibited cancer cell growth, affects CPS1 expression and function .

Emerging biological roles:

• Cancer metabolism: Further investigate how CPS1 maintains pyrimidine/purine balance in various cancer types .

• Cardiovascular implications: Explore how CPS1 variants impact cardiovascular health through antibody-based studies of protein function and expression .

• Non-canonical functions: Investigate potential extra-mitochondrial roles of CPS1 using subcellular fractionation combined with antibody detection.

• lncRNA interactions: Study how the CPS1-derived lncRNA CPS1-IT1 relates to CPS1 protein expression and function in cancer biology .